Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goodrich

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Diabetes Care|December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 StudyAvivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
The New England Journal of Medicine|January 22, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial FibrillationChristian T Ruff, Siddharth M Patel, Robert P Giugliano, et al.
Journal of the American College of Cardiology|June 11, 2025
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trialMeir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Journal of Rehabilitation Research and Development|November 9, 2013
Development of a mild traumatic brain injury-specific vision screening protocol: a Delphi studyGregory L Goodrich, Gary L Martinsen, Heidi M Flyg, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Diabetes Care|December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 StudyAvivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
The New England Journal of Medicine|January 22, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial FibrillationChristian T Ruff, Siddharth M Patel, Robert P Giugliano, et al.
Journal of the American College of Cardiology|June 11, 2025
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trialMeir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Journal of Rehabilitation Research and Development|November 9, 2013
Development of a mild traumatic brain injury-specific vision screening protocol: a Delphi studyGregory L Goodrich, Gary L Martinsen, Heidi M Flyg, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Pageof 12